194 results about "Carcinomatoses" patented technology

The present invention relates to methods for detecting, prognosing and staging cancers, in particular cancers of the gastrointestinal tract. The methods of the invention comprise detecting specific protein markers in a tissue of interest, wherein the detected levels thereof may be indicative of pre-cancerous or cancerous tissue, or the stage or prognosis of a cancer. Further provided are methods of treating cancer, and cancer detection kits.

An IV pole mountable, therapeutic infusate processing device is incorporated into a hypothermia system to receive therapeutic fluid(s), such as normal saline, peritioneal dialysis solution, or other crystalloid solution, to heat such therapeutic fluid(s) a few degrees centigrade above normal body temperature and to direct the resulting heated infusate to and through a selected anatomical portion of a patients body to raise the temperature of that body portion so as to affect any cancerous or other tumors that may be located therein. The processing device is provided with touch screen controls and visual indicators to facilitate its proper use; while the system further includes temperature and pressure sensors to monitor the hyperthermia processing to insure patient safety.

An anticancer high-molecular precursor medicine C-Spacer-P, where P is high- molecular pectin, C is an anticancer medicine containing amino radical or hydroxy radical, and Spacer is the spacing radical, is prepared by bonding the amino or hydroxy of an anticancer medicine with the hydroxy, carboxy, or hydroxymethyl of high- molecular pectin via spacing radical. It is an injection suitable for the solid cancer, and cancerous ascites or hydrothorax.

The invention relates to an aptamer-based targeted delivery microRNA nanometer carrier as well as a preparation method and application thereof. A targeting molecule is a sulfydryl-modified MUC-1molecule, and can be combined with cancer-inhibiting microRNA-34a, so that a MicroRNA-nanodiamond-protamine complex (MNPs) becomes AMNPs with an active targeting function; through electrostatic interaction, a negatively-charged aptamer-microRNA (Apt-miR) chimera is adsorbed to a cationic protamine-nanodiamond carrier to form a trinary compound carrier. The therapeutic effect of a nanotransport system on a non-small cell lung cancer is researched; the Apt-miR chimera is low in immunogenicity; the modified MUC-1 aptamer has high chemical stability in vivo, and can be chemically synthesized easily; in order to improve the transfection efficiency, a protamine-modified nanodiamond material (NPs) is used for helping miRNA to increase accumulation in a tumor part through permeability and retention enhancing effects.

The present invention aims to provide a compound having an MAGL inhibitory action, and useful as a prophylactic or therapeutic agent for neurodegenerative diseases (e.g., Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis and the like), anxiety disorder, pain (e.g., inflammatory pain, carcinomatous pain, nervous pain and the like), epilepsy and the like. The present invention relates to a compound represented by the formula (I):

wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

The present invention provides methods for determining which cancer patients are susceptible to arginine depletion therapy and methods for treating cancer. The present invention also provides methods for predicting the appropriateness of arginine deprivation therapy for a cancer patient. The methods generally comprise obtaining a tumor sample from the cancer patient and detecting the presence or absence of evidence of urea cycle enzyme expression in the tumor sample. The absence of evidence of urea cycle enzyme expression in the tumor sample is indicative of a cancer patient who is a candidate for arginine deprivation therapy, and the presence of evidence of urea cycle enzyme expression in said tumor sample is indicative of a cancer patient who is not a candidate for arginine deprivation therapy. Prior to, simultaneous with, or after testing the tumor sample, the method further comprises the steps of obtaining a non-cancerous sample from the cancer patient and detecting the presence or absence of evidence of urea cycle enzyme expression in the non-cancerous sample, wherein the absence of evidence of urea cycle enzyme expression in the non-cancerous sample and absence of evidence of urea cycle enzyme expression in the tumor sample is indicative of a cancer patient who is not a good candidate for arginine deprivation therapy, the presence of evidence of urea cycle enzyme expression in the non-cancerous sample and the absence of evidence of urea cycle enzyme expression in the tumor sample is indicative of a cancer patient who is a good candidate for arginine deprivation therapy, and the presence of evidence of urea cycle enzyme expression in the tumor sample is indicative of a cancer patient who is not a candidate for arginine deprivation therapy.

The present invention refers to a method of treating a cancerous or non-cancerous skin lesion of a subject, e.g. a human patient, by epidermal radioisotope therapy, a specialized type of brachytherapy, comprising the steps of (a) defining and marking an area of skin to be treated; (b) covering said area with a protective layer, e.g. a protective film or foil; (c) applying a tailor-made radioactive source by applying a layer of a radioactive source material on said protective layer, such that said area is covered by said material while any area not to be treated is spared; and (d) removing the radioactive source after a predetermined time period of irradiation.

A composition for treating cancer is provided. The composition is a hexosaminidase covalently attached to a cancer cell targeting ligand and improves selectively of the hexosaminidase for tumor cells. In certain embodiments, the hexosaminidase is alternately chitinase (N-acetyl-glucosaminohydrolase), chitosanase, or N-acetyl-hexosaminidase and the targeting ligand is either a monoclonal antibody, an antibody fragment immunospecific to a tumor cell or cancer cell antigen, epidermal growth factor (EGF), fibroblast growth factor (FGF), transferrin, or folic acid. Also provided is a method for treating cancerous tumors comprising administering the composition to a patient that has a cancerous tumor.

The invention relates to a method for the determination of a cancer diagnostic/therapeutic biomarker assay and drug-targets including the following steps: (a) identification of potential candidate protein/peptide biomarkers and drug-targets based on the measurement of protein/peptide constituent concentrations in tissue sample proteomes as well as serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and qualitatively selecting as potential candidate protein/peptide biomarkers those which show a pronounced differential behaviour between healthy and cancerous sample proteomes; (b) optional verification of the potential candidate protein/peptide biomarkers as identified in step (a) by quantitative mass spectrometric measurement of the potential candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and selecting as candidate protein/peptide biomarkers those which show a mass-spectrometrically measurable quantitative differential behaviour between healthy and cancerous sample proteomes; (c) validation of the candidate protein/peptide biomarkers as identified in step (a), or as optionally verified in step (b), by mass spectrometric measurement and/or antibody-based assays such as an Enzyme-Linked Immunosorbent Assay (ELISA) determination of the candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy human individuals as well as from cancerous human individuals and selecting as protein/peptide biomarkers those which show a mass-spectrometrically measurable and/or antibody-based assay detectable differential behaviour between healthy and cancerous sample proteomes; (d) application of statistical methods to uncover single or groups of protein/peptide biomarkers as validated in step (c) as signatures for the detection of patients with cancer. The invention furthermore relates to specific biomarker assays for the highly reliable diagnosis of cancer, specifically of localized or non-localized prostate cancer, using human serum, plasma or any other derivatives of blood, or blood itself.

The present invention concerns the use of E6 and/or E7 peptides from human papilloma virus (HPV) to evaluate a cell-mediated response in a patient infected with HPV to determine the prognosis for that patient with respect to the development or recurrence of pre-cancerous or cancerous growths, including cervical intraepithelial neoplasia (CIN).

The present invention relates to a novel composition and method for loading delivery systems such as liposome compositions with radionuclides useful in targeted diagnostic and/or therapy of target site, such as cancerous tissue and, in general, pathological conditions associated with leaky blood vessels. The composition and methods of the invention find particular use in diagnosing and imaging cancerous tissue and, in general, pathological conditions associated with leaky blood vessels in a subject. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique. One specific aspect of the invention is directed to a method of producing nanoparticles with desired targeting properties for diagnostic and/or radio-therapeutic applications.

The present invention relates to devices, systems and methods for treating tumors. In particular, the present invention relates to enclosures housing cell-coated supports for promoting regression of tumors, such as cancerous tumors, papillomas, and warts. In preferred embodiments, the present invention provides methods of promoting tumor regression employing enclosures secreting therapeutic proteins.

The invention provides a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal in need thereof which comprises administering to said mammal an effective amount of a substituted triazolopyrimidine derivative or a pharmaceutically acceptable salt thereof and further provides a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal in need thereof by interacting with tubulin and microtubules and promoting microtubule polymerization which comprises administering to said mammal an effective amount of a substituted triazolopyrimidine derivative or a pharmaceutically acceptable salt thereof.

A composite medicine for treating rheumatic and rheumatoid diseases and cancer pain is prepared from Sailonggu, snow lotus flower and safflower. Its preparing process and its quality control method are also disclosed.

The invention belongs to the field of medicine technology, particularly relates to an application of a compound having the following structural formula as described in the specification in preparation of cancer pain medicines, and also relates to a pharmaceutical composition containing the compound.

The invention relates to a traditional Chinese medicine composition for treating cancer pain. The traditional Chinese medicine composition is prepared from the following raw medicines in parts by weight: 10 to 20 parts of sangusis draconis, 10 to 20 parts of borneol, 10 to 20 parts of frankincense, 10 to 20 parts of myrrh, and 10 to 20 parts of radix angelicae. The traditional Chinese medicine composition is in one of the common forms of externally-applied preparations. The traditional Chinese medicine composition has the advantages that various medicines supplement each other to realize the effects of promoting blood circulation to remove blood stasis, and eliminating stagnation and relieving pain; the effect of relieving cancer pain caused by liver cancer is obvious; the quality of life of a patient can be obviously improved; the satisfaction is high; the treatment effect is quickly achieved; in addition, the traditional Chinese medicine composition is an externally-applied preparation which is convenient to use, and the gastrointestinal reaction caused by orally taking the medicine is avoided; simultaneously, the traditional Chinese medicine is low in price and easily accepted by a patient.